What is Bunnell?
Bunnell Inc. operates at the intersection of advanced engineering and neonatal critical care, specializing in high-frequency jet ventilation systems. The company is recognized for its flagship LifePulse 203 and 204 platforms, which are engineered to provide gentle, effective respiratory support for the most vulnerable patient populations. By prioritizing physiologic impact and therapeutic flexibility, Bunnell has established a robust market position within hospitals and neonatal intensive care units globally. Their business model integrates high-precision hardware manufacturing with a deep commitment to clinical education, ensuring that healthcare providers are equipped with the necessary resources to manage complex respiratory conditions in infants and pediatric patients effectively.
How much funding has Bunnell raised?
Bunnell has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Bunnell
PPP
Public-Private Partnership
What's next for Bunnell?
With the infusion of this recent financing, Bunnell is poised to scale its research and development initiatives, focusing on the next generation of respiratory support technology. The strategic allocation of these funds will likely prioritize the expansion of clinical training programs and the optimization of supply chain logistics to meet the growing demand for high-frequency ventilation solutions. As the company transitions through this late-stage growth phase, the focus will remain on maintaining its standard of care while exploring potential integrations of digital health monitoring to further improve patient outcomes in neonatal care settings. This capital deployment serves as a catalyst for sustained innovation in a highly specialized medical niche.
See full Bunnell company page
